Clinical Trial

UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

Study acronym: T2DM
Completed Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-01.
Status change: Active, Not Recruiting → Completed 2026-05-06
Trial Details
NCT Number NCT07163624
Lead Sponsor The United Bio-Technology (Hengqin) Co., Ltd.
Conditions Type 2 Diabetes Mellitus (T2DM)
Enrollment 211 participants
Start Date 2025-03-22
Primary Completion 2025-11-21 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-07